Reagent | Non-Esterified Fatty Acid (NEFA)
Non-Esterified Fatty Acid (NEFA): A Marker of Insulin Resistance
Benefits of the Randox NEFA Assay
A correlation coefficient of r=0.98 was displayed when the Randox NEFA assay was compared to commercially available methods.
Applications available detailing instrument-specific settings for the convenient use of the Randox NEFA assay on a variety of clinical chemistry analsyers.
Extensive measuring range
The Randox NEFA assay has a measuring range of 0.072 – 2.24mmol/l for the comfortable detection of clinically important results.
Standard supplied with the kit
The Randox NEFA kit includes the standard simplifying the ordering process.
Controls available offering a complete testing package.
The Randox NEFA assay displayed a precision of <5% CV.
|FA115||R1 3 x 10ml (C) |
R2 3 x 20ml
|Enquire||Kit Insert Request||MSDS||Buy Online|
|(C) Indicates calibrator included in kit|
Instrument Specific Applications (ISA’s) are available for a wide range of biochemistry analysers. Contact us to enquire about your specific analyser.
Non-esterified fatty acids are important metabolites stored in adipose tissue. NEFA turnover is swift, with a plasma half – life of 2 to 4 minutes. The dominant source of NEFA is abdominal subcutaneous fat, with considerably less found in leg adipose tissue and a small proportion found in the intraabdominal adipose tissue. NEFA has been recognised as a vehicle by which triacylglycerol (TG) (stored in the adipose tissue) is transported to its sites of utilisation 1. NEFA has been identified as the major source for skeletal muscle during fasting stages and long periods between meals. Cross – sectional studies have consistently documented that circulating NEFA levels are proportional to body fat storage and demonstrated positive correlations between fasting NEFA levels and obesity, insulin resistance and glucose tolerance 2.
Non-esterified fatty acids concentrations are strongly associated with insulin resistance. In the fasting state, the resistance of adipose tissue to the antilipolytic effect of insulin causes the extensive release of NEFA into circulation. Consequently, elevated NEFA levels exacerbate insulin resistance through diminishing insulin – stimulated glucose intake into the skeletal muscle, directly affecting insulin signalling 3.
Clinical Chemistry Controls
Clinical Chemistry EQA
 Karpe F, Dickmann JR, Frayn KN. Fatty Acids, Obesity, and Insulin Resistance: Time for a Reevaluation. Diabetes 2011; 60(10): 2441-2449.
 Il’yasova D, Wang F, D’Agostino RB Jr, Hanley A, Wagenknecht LE. Prospective association between fasting NEFA and type 2 diabetes: impact of post-load glucose. Diabetologia 2010; 53(5): 866-874.
 Saad MI, Kamel MA, Hanafi MY. Modulation of Adipocytokines Production and Serum NEFA Level by Metformin, Glimepiride, and Sitagliptin in HFD/STZ Diabetic Rats. Biochemistry Research International 2015; 2015(138134): https://www.hindawi.com/journals/bri/2015/138134/ (accessed 7 August 2019).